I am CEO and co-founder of MiDx. Our vision is to achieve rapid (<20 minutes) point of care microbial diagnostics, ultimately taking this out of the hospital and into the home care setting.
At MiDx we have developed the worlds first urine based lateral flow test for the detection of Pseudomonas aeruginosa in respiratory tract infections using our patented biomarkers. Our first indication is Cystic Fibrosis where sputum is not as readily available, our clinical work has proven that P. aeruginosa can be detected in urine of people with CF.
We received a prestigious IUK ICURe Exploit grant (Apr 24 – Mar 25). To further our diagnostic capacity we are developing a pipeline of other mircrobial biomarkers with a focus on priority respiratory pathogens